The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices

Badrinath Konety; Stephen M Zappala; Dipen J Parekh; Danielle Osterhout; Jeffrey Schock; Randy M Chudler; Gregory M Oldford; Kenneth M Kernen; Jason Hafron

The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices

Rev Urol. 2015;17(4):231-40.

Authors

Badrinath Konety¹, Stephen M Zappala², Dipen J Parekh³, Danielle Osterhout⁴, Jeffrey Schock⁴, Randy M Chudler⁴, Gregory M Oldford⁴, Kenneth M Kernen⁴, Jason Hafron⁴

Affiliations

¹ Department of Urology, University of Minnesota, Minneapolis, MN.
² Department of Urology, Tufts University School of Medicine, Boston, MA.
³ Department of Urology, University of Miami Miller School of Medicine, Miami, FL.
⁴ Michigan Institute of Urology, St. Clair Shores, MI.

PMID: 26839521
PMCID: PMC4735670

Abstract

There is significant concern regarding prostate cancer screening because of the potential for overdiagnosis and overtreatment of men who are discovered to have abnormal prostate specific antigen (PSA) levels and/or digital rectal examination (DRE) results. The 4Kscore® Test (OPKO Diagnostics, LLC) is a blood test that utilizes four kallikrein levels plus clinical information in an algorithm to calculate an individual's percentage risk (< 1% to > 95%) for aggressive prostate cancer (Gleason score ≥ 7) on prostate biopsy. The 4Kscore Test, as a follow-up test after abnormal PSA and/or DRE test results, has been shown to improve the specificity for predicting the risk of aggressive prostate cancer and reduce unnecessary prostate biopsies. A clinical utility study was conducted to assess the influence of the 4Kscore Test on the decision to perform prostate biopsies in men referred to urologists for abnormal PSA and/or DRE results. The study population included 611 patients seen by 35 academic and community urologists in the United States. Urologists ordered the 4Kscore Test as part of their assessment of men referred for abnormal PSA and/or DRE test results. Results for the patients were stratified into low risk (< 7.5%), intermediate risk (7.5%-19.9%), and high risk (≥ 20%) for aggressive prostate cancer. The 4Kscore Test results influenced biopsy decisions in 88.7% of the men. Performing the 4Kscore Test resulted in a 64.6% reduction in prostate biopsies in patients; the actual percentage of cases not proceeding to biopsy were 94.0%, 52.9%, and 19.0% for men who had low-, intermediate-, and high-risk 4Kscore Test results, respectively. A higher 4Kscore Test was associated with greater likelihood of having a prostate biopsy (P < 0.001). Among the 171 patients who had a biopsy, the 4Kscore risk category is strongly associated with biopsy pathology. The 4Kscore Test, as a follow-up test for an abnormal PSA and/or DRE results, significantly influenced the physician and patient shared decision in clinical practice, which led to a reduction in prostate biopsies while increasing the probability of detecting aggressive cancer.

Keywords: 4Kscore Test; Biopsy rate; Digital rectal examination; Gleason score; Prostate cancer; Prostate cancer prognosis; Prostate-specific antigen.